➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Boehringer Ingelheim

Last Updated: September 28, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,993,520

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,993,520 protect, and when does it expire?

Patent 8,993,520 protects AXIRON and is included in one NDA.

This patent has twenty patent family members in thirteen countries.

Summary for Patent: 8,993,520
Title:Method and composition for transdermal drug delivery
Abstract: The invention is directed to a transdermal drug delivery composition which includes at least one physiologically active agent; and at least one volatile solvent; and at least one viscosity modulating agent. The invention extends to methods of administering such a composition to a subject and treatment of subjects using the composition.
Inventor(s): Dipietro; Tony (Victoria, AU), Humberstone; Andrew (Victoria, AU), Gonda; Igor (South Yarra, AU), Watkinson; Adam (Victoria, AU), Setiawan; Kerrie (Victoria, AU), Wilkins; Nina (Victoria, AU)
Assignee: Acrux DDS Pty Ltd (West Melbourne, Victoria, AU)
Application Number:12/823,448
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,993,520
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery; Device;

Drugs Protected by US Patent 8,993,520

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Eli Lilly And Co AXIRON testosterone SOLUTION, METERED;TRANSDERMAL 022504-001 Nov 23, 2010 DISCN Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF AN ADULT MALE SUBJECT IN NEED THEREOF ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,993,520

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Australia2005902902Jun 3, 2005

International Family Members for US Patent 8,993,520

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2006254742 ⤷  Free Forever Trial
Australia 2011202787 ⤷  Free Forever Trial
Brazil PI0611134 ⤷  Free Forever Trial
Canada 2610708 ⤷  Free Forever Trial
China 101212975 ⤷  Free Forever Trial
China 102091079 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.